AFRIN ORIGINAL OTC
Generic Name and Formulations:
Oxymetazoline HCl 0.05%; nasal spray.
Merck & Co., Inc.
Indications for AFRIN ORIGINAL:
Adults and Children:
<6yrs: individualize. ≥6yrs: 2–3 sprays in each nostril not more than every 10–12 hours. Max 2 doses/day.
Use >3 days; may worsen nasal congestion.
Heart disease. Hypertension. Thyroid disease. Diabetes. Urinary retention. Enlarged prostate. Pregnancy. Nursing mothers.
Local effects (eg, burning, stinging, sneezing, increased nasal discharge).
Original nasal spray—30mL; No Drip Original, Severe Congestion, Extra Moisturizing, Sinus—15mL
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds